| Literature DB >> 24195069 |
Alireza Akbarzadeh Baghban1, Asma Pourhoseingholi, Farid Zayeri, Ali Akbar Jafari, Seyed Moayed Alavian.
Abstract
BACKGROUND AND OBJECTIVES: In recent years, hepatitis C virus (HCV) infection represents a major public health problem. Evaluation of risk factors is one of the solutions which help protect people from the infection. This study aims to employ zero-inflated Poisson mixed models to evaluate prognostic factors of hepatitis C.Entities:
Mesh:
Year: 2013 PMID: 24195069 PMCID: PMC3806337 DOI: 10.1155/2013/403151
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
The distribution of covariates in this study.
| Variable | Category |
| % |
|---|---|---|---|
| Sex | Female | 55 | 29.6 |
| Male | 131 | 70.4 | |
| Risk factor | Yes | 104 | 55.9 |
| No | 82 | 44.1 | |
| Genotype | 1 | 142 | 76.3 |
| 2 | 4 | 2.2 | |
| 3 | 40 | 21.5 | |
| Treatment | Interferon plus Ribavirin | 100 | 53.8 |
| Peg-Interferon plus Ribavirin | 86 | 46.2 |
The distribution of six groups of viral load in 186 patients.
| Viral load | Male | Female | Total | |||
|---|---|---|---|---|---|---|
|
| % |
| % |
| % | |
| Zero | 289 | 55.2 | 116 | 52.7 | 405 | 54.5 |
| 200 to 200,000 | 78 | 14.9 | 36 | 16.4 | 114 | 15.3 |
| 200,000 to 1,000,000 | 110 | 21 | 45 | 20.5 | 155 | 20.8 |
| 1,000,000 to 5,000,000 | 40 | 7.6 | 21 | 9.5 | 61 | 8.2 |
| 5,000,000 to 25,000,000 | 7 | 1.3 | 1 | 0.5 | 8 | 1.1 |
| Above 25,000,000 | 0 | 0 | 1 | 0.5 | 1 | 0.1 |
|
| ||||||
| Total | 524 | 100 | 220 | 100 | 744 | 100 |
The results of mixed PR model.
| Parameter | Category | Estimated | Standard error |
|
|---|---|---|---|---|
| Intercept | 0.7320 | 0.188 | <0.001 | |
| Age | 0.0049 | 0.0036 | 0.195 | |
| Sex | Female* | |||
| Male | −0.0487 | 0.0864 | 0.580 | |
| Riskfactor | No* | |||
| Yes | 0.154 | 0.0803 | 0.053 | |
| Genotype | 1* | |||
| 2 | −0.1760 | 0.2785 | 0.539 | |
| 3 | −0.2357 | 0.0984 | 0.013 | |
| Treatment | Interferon plus Ribavirin* | |||
| Peg-Interferon plus Ribavirin | −0.2584 | 0.0728 | 0.001 | |
| Variance component | 0.2469 | <0.001 |
*Reference group.
The results of mixed ZIP model.
| Parameter | Category | Estimated | Standard error |
|
|---|---|---|---|---|
| Intercept | 3.6517 | 0.1659 | <0.001 | |
| Age | 0.0046 | 0.0023 | 0.037 | |
| Sex | Female* | |||
| Male | −0.978 | 0.0833 | <0.001 | |
| Risk factor | No | |||
| Yes | 0.4626 | 0.074 | <0.001 | |
| Genotype | 1* | |||
| 2 | −0.8006 | 0.2381 | <0.001 | |
| 3 | −1.148 | 0.0932 | <0.001 | |
| Treatment | Interferon plus Ribavirin* | |||
| Peg-Interferon plus Ribavirin | −0.6628 | 0.0737 | <0.001 | |
|
| 0.6891 | |||
|
| 1.6153 | |||
|
| 0.3634 |
*Reference group.
The comparison of mixed ZIP and mixed PR.
| Parameter | Category | Mixed ZIP model | Mixed PR model | ||
|---|---|---|---|---|---|
| Estimated | Standard error | Estimated | Standard error | ||
| Intercept | 3.6517 | 0.1659 | 0.7320 | 0.188 | |
| Age | 0.0046 | 0.0023 | 0.0049 | 0.0036 | |
| Sex | Female* | ||||
| Male | −0.978 | 0.0833 | −0.0487 | 0.0864 | |
| Risk factor | No | ||||
| Yes | 0.4626 | 0.074 | 0.154 | 0.0803 | |
| Genotype | 1* | ||||
| 2 | −0.8006 | 0.2381 | −0.1760 | 0.2785 | |
| 3 | −1.148 | 0.0932 | −0.2357 | 0.0984 | |
| Treatment | Interferon plus Ribavirin* | ||||
| Peg-Interferon plus Ribavirin | −0.6628 | 0.0737 | −0.2584 | 0.0728 | |
*Reference group.